NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCE NK30424A AND NK3024 B, THEIR PRODUCTION AND USE

Publication number: JP11127882 (A)

Publication date:

1999-05-18

Inventor(s):

TAKAYASU YOSHIYUKI; YAMAZAKI TADAO; AOYAMA TAKAYUKI; HARADA

TAKASHI

Applicant(s):

NIPPON KAYAKU KK

Classification:

- international:

C12P1/06; A61K31/335; C12R1/465; C12P1/06; A61K31/335; (IPC1-7): C12P1/06;

A61K31/335; C12P1/06; C12R1/465

- European:

Application number: JP19970309505 19971027 Priority number(s): JP19970309505 19971027

Abstract of JP 11127882 (A)

PROBLEM TO BE SOLVED: To provide the subject novel substance that is obtained from a microorganism in Streptomyces capable of producing a physiologically active substances NK3042A and NK3024B, has the TNF &alpha production inhibitory action and is useful for treatment and prevention of rheumatoid arthritis, Kawasaki disease, cancer cachexia, and the like. SOLUTION: This novel substances have the following physical and chemical properties: appearance, white powder; melting point, 129-131 deg.C (decomposition); molecular formula, C30 H46 N2 O10 S; Molecular weight, 626; solubility, readily soluble in water, methanol and dimethyl sulfoxide; soluble in methanol; insoluble in nhexane and ethyl acetate; the color reactions, positive to Rydon-Smith, ninhydrin, sulfuric acid and potassium permanganate; negative to Ehrlich, Skaguchi, and Dragendorff; the Rf value, 0.5 according to the silica gel thin layer chromatography with an eluent solvent of I-butanol-acetic acid-water (4:1:1). These compounds, NK30424 A or B (or their salts) are useful for treatment and prevention of rheumatoid arthritis, Kawasaki disease, Crohn disease, Behcet's disease, bronchial asthma, cancer cachexia, septicemia, multiple sclerosis, and dementia.

Data supplied from the esp@cenet database — Worldwide